Items where authors include "Duncan, C"

Article

Hardt, K, Vandebosch, A, Sadoff, J et al. (285 more authors) (2022) Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, 22 (12). pp. 1703-1715. ISSN 1473-3099

Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736

Angyal, A, Longet, S, Moore, SC et al. (176 more authors) (2022) T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe, 3 (1). e21-e31. ISSN 2666-5247

Jain, N, Sattar, S, Inglott, S et al. (10 more authors) (2021) Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma. F1000Research, 10. 947. ISSN 2046-1402

Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736

Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736

Conference or Workshop Item

Ferrada, M, Savic, S, Alessi, H et al. (18 more authors) (2021) Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features. In: ACR Convergence 2021, 05-09 Nov 2021, Virtual.